James Andrews
Psychiatry · Atlanta, GANPI 1710017132
Payments from drug & device makers
Across 634 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$926
- Lundbeck LLC$877
- Ironshore Pharmaceuticals Inc.$723
- plus $6K from 26 others
What the payments were for
- Speaking & faculty fees$5004%
- Food & beverage$12,12496%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 59 | $1,867 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $1,094 |
| Otsuka America Pharmaceutical, Inc. | 60 | $1,092 |
| AbbVie(2 entities) | 62 | $926 |
| Lundbeck LLC | 52 | $877 |
| Ironshore Pharmaceuticals Inc. | 33 | $723 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $645 |
| Johnson & Johnson | 31 | $616 |
| Tris Pharma Inc | 31 | $609 |
| Corium, LLC | 28 | $529 |
| Bausch Health US, LLC | 26 | $509 |
| Neurocrine Biosciences, Inc. | 23 | $429 |
| Sunovion Pharmaceuticals Inc. | 24 | $382 |
| Axsome Therapeutics, Inc. | 14 | $369 |
| Noven Therapeutics, LLC | 14 | $282 |
| Neos Therapeutics, LP | 15 | $246 |
| Teva Pharmaceuticals USA, Inc. | 12 | $205 |
| Idorsia Pharmaceuticals US Inc | 10 | $182 |
| Collegium Pharmaceutical, Inc. | 9 | $168 |
| Vanda Pharmaceuticals Inc. | 8 | $145 |
| Shire North American Group Inc | 7 | $139 |
| Merck | 6 | $103 |
| Adlon Therapeutics L.p. | 5 | $88 |
| Alfasigma USA, Inc. | 6 | $87 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Brainsway USA Inc | 2 | $53 |
| Eisai Inc. | 3 | $49 |
| Avanir Pharmaceuticals, Inc. | 3 | $45 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Alkermes, Inc. | 1 | $25 |
| Noven Pharmaceuticals, Inc. | 1 | $19 |
| Lifenet Health | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$170
How this compares
$12,624 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AplenzinBupropion Hbr | 11 | $64,088 |
| TrintellixVortioxetine Hydrobromide | 67 | $52,678 |
| AmbienZolpidem Tartrate | 12 | $7,432 |
| Lisdexamfetamine Dimesylate | 28 | $6,170 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $6,109 |
| Vilazodone Hcl | 17 | $2,751 |
| Bupropion XlBupropion Hcl | 98 | $2,354 |
| Escitalopram Oxalate | 125 | $1,604 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 67 | $1,281 |
| Trazodone Hcl | 133 | $1,095 |
| Mirtazapine | 52 | $1,049 |
| Duloxetine Hcl | 35 | $1,014 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $869 |
| Sertraline Hcl | 74 | $767 |
| Methylphenidate Hcl | 30 | $658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch Health US, LLCAplenzin | $509 | $64,08811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $645 | $58,78780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Bethany DavisAtlanta$4.4M
- Patricio Riva PosseAtlanta$884K
- Kerry ResslerAtlanta$365K
- Boadie DunlopAtlanta$345K
- Michael BurkeAtlanta$328K
- Bryon EvansAtlanta$211K
- Nurul HoqueAtlanta$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.